119 related articles for article (PubMed ID: 15238426)
1. Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens.
Tang Y; Zhang L; Yuan J; Akbulut H; Maynard J; Linton PJ; Deisseroth A
Blood; 2004 Nov; 104(9):2704-13. PubMed ID: 15238426
[TBL] [Abstract][Full Text] [Related]
2. Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer.
Akbulut H; Tang Y; Akbulut KG; Maynard J; Zhang L; Deisseroth A
Mol Cancer Ther; 2006 Aug; 5(8):1975-85. PubMed ID: 16928818
[TBL] [Abstract][Full Text] [Related]
3. TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases.
Deisseroth A; Tang Y; Zhang L; Akbulut H; Habib N
Cancer Gene Ther; 2013 Feb; 20(2):65-9. PubMed ID: 23238593
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy targeted to cancer tissue potentiates antigen-specific immune response induced by vaccine for in vivo antigen loading and activation of dendritic cells.
Akbulut H; Tang Y; Akbulut KG; Maynard J; Deisseroth A
Mol Ther; 2008 Oct; 16(10):1753-60. PubMed ID: 18728641
[TBL] [Abstract][Full Text] [Related]
5. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells.
Zhang L; Tang Y; Akbulut H; Zelterman D; Linton PJ; Deisseroth AB
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15101-6. PubMed ID: 14645711
[TBL] [Abstract][Full Text] [Related]
6. Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancer.
Tang Y; Akbulut H; Maynard J; Petersen L; Fang X; Zhang WW; Xia X; Koziol J; Linton PJ; Deisseroth A
J Immunol; 2006 Oct; 177(8):5697-707. PubMed ID: 17015759
[TBL] [Abstract][Full Text] [Related]
7. Addition of adenoviral vector targeting of chemotherapy to the MUC-1/ecdCD40L VPPP vector prime protein boost vaccine prolongs survival of mice carrying growing subcutaneous deposits of Lewis lung cancer cells.
Akbulut H; Tang Y; Akbulut KG; Maynard J; Deisseroth A
Gene Ther; 2010 Nov; 17(11):1333-40. PubMed ID: 20596057
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.
Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT
Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
10. Vector prime protein boost vaccination in the setting of myeloablative-induced lymphopenia suppresses growth of leukemia and solid tumors.
Han TH; Tang Y; Park YH; Maynard J; Li P; Akbulut H; Petersen L; Deisseroth A
Bone Marrow Transplant; 2010 Mar; 45(3):550-7. PubMed ID: 19648971
[TBL] [Abstract][Full Text] [Related]
11. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM
J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245
[TBL] [Abstract][Full Text] [Related]
12. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma.
Tan TJ; Ang WXG; Wang WW; Chong HS; Tan SH; Cheong R; Chia JW; Syn NL; Shuen WH; Ba R; Kaliaperumal N; Au B; Hopkins R; Li X; Tan AC; Seet AOL; Connolly JE; Arkachaisri T; Chew V; Lajam ABM; Guo D; Chew MZW; Wasser M; Kumar P; Albani S; Toh HC
Nat Commun; 2022 Oct; 13(1):6453. PubMed ID: 36307410
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC
Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449
[TBL] [Abstract][Full Text] [Related]
16. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine.
Hangalapura BN; Oosterhoff D; de Groot J; Boon L; Tüting T; van den Eertwegh AJ; Gerritsen WR; van Beusechem VW; Pereboev A; Curiel DT; Scheper RJ; de Gruijl TD
Cancer Res; 2011 Sep; 71(17):5827-37. PubMed ID: 21747119
[TBL] [Abstract][Full Text] [Related]
17. Enhanced induction of anti-tumor CTLs in vitro by a lentivirus-transduced dendritic cell vaccine expressing secondary lymphoid tissue chemokine and mucin 1.
Wang B; Zhu Y; Zhang JJ; Chen Z; Liang WB; Xu ZK
Asian Pac J Cancer Prev; 2011; 12(11):2811-7. PubMed ID: 22393946
[TBL] [Abstract][Full Text] [Related]
18. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
[TBL] [Abstract][Full Text] [Related]
19. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
20. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
